Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

November 19th 2024

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).

Don M. Benson, MD, PhD, James Cancer Hospital
Elevating Myeloma Care Amidst Complex Treatment Choices

November 15th 2024

Neon CAR T graphic | Image Credit: © kalpis-stock.adobe.com
Eque-Cel CAR T Shows Strong Results for Multiple Myeloma

November 7th 2024

Screenshot of an interview with Courtney VanHouzen, PharmD
Making Cancer Care Easier With Community Bispecific Antibody Programs

October 15th 2024

Thomas Jefferson | Image: Thomas Jefferson University
Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy

October 13th 2024

EHA 2024: Highlights in Multiple Myeloma

Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.

Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.
Continuing Medical Education
View All
November 21st 2024

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

December 18, 2024 | 1:00 PM & 8:00 PM ET
November 21st 2024

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.0 Credits / Hematologic Cancer, Oncology
November 21st 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
November 21st 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

More News

Patient and Doctor
January 25th 2023

In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age Groups

Mary Caffrey
An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.
Product Preference with NCCN Category 1 Status
January 25th 2023

Product Preference with NCCN Category 1 Status

Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.
Providing Incentives for Provider Adherence to MM Pathway
January 25th 2023

Providing Incentives for Provider Adherence to MM Pathway

Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.
Study Finds Ixazomib Beneficial in MM Patients With High-Risk Cytogenic Traits
January 20th 2023

Study Finds Ixazomib Beneficial in MM Patients With High-Risk Cytogenic Traits

Rose McNulty
A recent study found that ixazomib was associated with better progression-free survival versus a placebo in multiple myeloma regardless of cytogenetic risk status.
Clinical Collaboration Driving MM Treatment Pathways
January 18th 2023

Clinical Collaboration Driving MM Treatment Pathways

Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.
Clinical Pathways Guiding Treatment Selection in Multiple Myeloma
January 18th 2023

Clinical Pathways Guiding Treatment Selection in Multiple Myeloma

A panel of experts discuss the value of clinical pathways in MM disease management.
Disparities in Multiple Myeloma: Quality Improvement Initiative Reveals Gaps Between Oncology Providers, Patients in Views of Costs, Risk of Treatments
January 12th 2023

Disparities in Multiple Myeloma: Quality Improvement Initiative Reveals Gaps Between Oncology Providers, Patients in Views of Costs, Risk of Treatments

Interview by Mary Caffrey
An interview with Joseph R. Mikhael, MD, MEd, on findings from a Quality Improvement initiative presented during the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana. Mikhael is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, in Phoenix, Arizona.
Utilizing Available Frontline Treatment in MM
January 11th 2023

Utilizing Available Frontline Treatment in MM

Daratumumab can be an effective frontline MM treatment option.
Adequate Treatment Response in Transplant-Ineligible MM Patients
January 11th 2023

Adequate Treatment Response in Transplant-Ineligible MM Patients

Raymond Thertulien, MD, PhD, discusses high-risk factors for patients with MM.
Black patient.
January 11th 2023

Spotlighting Health Disparities for Black Americans With Multiple Myeloma and Potential Solutions

Matthew Gavidia
Black Americans with multiple myeloma face disparities in incidence of disease, survival outcomes, and use of evidence-based treatment, which may be exacerbated by socioeconomic factors.
Doctor and patient.
January 9th 2023

Disparities in Multiple Myeloma Treatment, Mortality Risk Observed Among Hispanic Americans

Matthew Gavidia
Despite greater incidence of multiple myeloma (MM) reported among Hispanic Americans, these populations report less MM maintenance therapy, longer time from MM diagnosis to novel therapy initiation, and higher in-hospital mortality rates.
Patient Frailty Impacting Multiple Myeloma (MM) Treatment Strategies
January 4th 2023

Patient Frailty Impacting Multiple Myeloma (MM) Treatment Strategies

Brea C. Lipe, MD, highlights considerations for frail patients when treating for MM.
SWOG777 Trial and DRd vs VRd
January 4th 2023

SWOG777 Trial and DRd vs VRd

Medical experts explore the SWOG-S0777 trial and present an overview of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs bortezomib, lenalidomide, and low-dose dexamethasone (VRd).
Top 5 articles on AJMC.com.
January 1st 2023

Top 5 Most-Read Articles on AJMC.com for 2022

Matthew Gavidia
The top 5 most-read articles on AJMC.com for 2022 covered COVID-19, the first treatment for repigmentation in vitiligo, migraine care, and vitamin D supplementation for patients with multiple myeloma.
M. Hossein Kazemi, medical oncologist and hematologist, Astera Cancer Care
December 31st 2022

Dr Hossein Kazemi: What Patients With MM Consider When Stopping Therapy

Pearl Steinzor
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses the benefits of de-escalating treatment for patients with multiple myeloma.
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care
December 24th 2022

Dr Hossein Kazemi on Identifying Eligible Patients With MM for De-escalation

Pearl Steinzor
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses emerging tools to use to identify patients with multiple myeloma for de-escalating treatment.
A graphic of the title with health icons
December 22nd 2022

Top 5 Most-Read Multiple Myeloma News of 2022

Justina Petrullo
The most-read multiple myeloma (MM) articles of the year included the topics of novel treatments, the role of gene expression influence on MM, and more.
MAIA Study and Subgroup Analysis
December 21st 2022

MAIA Study and Subgroup Analysis

Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study.
Front-line Treatment Management for Patients with Multiple Myeloma (MM)
December 21st 2022

Front-line Treatment Management for Patients with Multiple Myeloma (MM)

Key opinion leaders open a discussion surrounding the current treatment landscape of multiple myeloma (MM).
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care
December 17th 2022

Dr Hossein Kazemi Discusses De-escalating Treatment Tools for Patients With Multiple Myeloma

Pearl Steinzor
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, identifies key tools in de-escalating treatment for patients with multiple myeloma.
Astera Cancer Care Shows How Community Oncology Can Innovate Both in the Clinic and in Contracting
December 2nd 2022

Astera Cancer Care Shows How Community Oncology Can Innovate Both in the Clinic and in Contracting

Mary Caffrey
Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.
Image of nurse administering palliative care
December 1st 2022

End-of-Life Care in Multiple Myeloma Still Requires Fine-tuning, Despite Improvements

Rose McNulty
Thirteen years of population-based data highlight substantial rates of aggressive end-of-life care and disparities in care within a publicly funded health care system in Ontario, Canada.
Graphic representing COVID-19 risk
November 29th 2022

Predictors of Severe COVID-19 Infection, Mortality in Patients With MM, AL Identified

Jaime Rosenberg
Their findings, say the researchers, offer useful insights into the outcomes and risks of severe disease and mortality in patients who have multiple myeloma (MM) or amyloidosis (AL) with underlying monoclonal gammopathy who contract COVID-19.
Image of a reengineered cell
November 18th 2022

CAR T-Cell Therapy Can Work as Salvage Treatment in Relapsed MM Following BCMA-Directed CAR T

Jared Kaltwasser
New data show patients treated with chimeric antigen receptor (CAR) T-cell therapy as salvage therapy tended to have meaningful results despite treatment failure following B-cell maturation antigen (BCMA) CAR T.
Image of an electronic medical record
November 14th 2022

EHR Data Show MM Treatment Burden Higher Than Chronic Lymphoid Leukemia

Jared Kaltwasser
This new study shows how using electronic health record (EHR) data can objectively quantify patient treatment burden among individuals who have multiple myeloma (MM) compared with patient-reported outcomes, which can be subject to recall bias.
Joseph Alvarnas, MD.
November 12th 2022

Dr Joseph Alvarnas: Cancer Care Equity Act Meets the Needs of Patients With Advanced Disease

Matthew Gavidia
Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke on how the California Cancer Care Equity Act will allow oncologists to escalate the care of patients with advanced cancers toward established centers that can better meet their needs, as well as implications from the decision to exclude genomic testing coverage in the bill.
graphic depicting time
November 12th 2022

Shorter Time to Treatment Is Associated With Worse OS in Multiple Myeloma, Study Finds

Rose McNulty
The study highlights a need for further research into potential contributors, including the possibility that sicker patients may receive more prompt treatment.
Bhavesh Shah
November 7th 2022

Bhavesh Shah Discusses Expanding Access for BCMA Bispecific Antibody

Hayden E. Klein
Bhavesh Shah, RPh, BCOP, chief pharmacy officer and director of specialty and hematology/oncology pharmacy at Boston Medical Center, talks about what oncology agents in the pipeline he hopes to see become available.
FDA approved
October 26th 2022

FDA Approves First Bispecific Antibody, Teclistamab, for R/R Multiple Myeloma

Christina Mattina
The FDA’s approval of teclistamab for relapsed/refractory (R/R) multiple myeloma makes it the first bispecific T-cell engager antibody to enter the treatment landscape.
image of smartphone
October 20th 2022

Can Digital Exercise Benefit Patients With Multiple Myeloma?

Mary Caffrey
Although exercise during cancer treatment is encouraged, multiple myeloma can present special challenges, since there is an increased risk of bone fractures, pain, and other deformities.
<12345678910>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo